Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30727530 | 1.00 | CRBN (0.93) | — | |
| Hydrochloric Acid SCHEMBL29153064 | 1.00 | CRBN (0.93) | — | |
| Hydrochloric Acid SCHEMBL31554744 | 1.00 | CRBN (0.93) | — | |
| SCHEMBL26618 | 0.96 | — | — | |
| SCHEMBL5778743 | 0.96 | CRBN (1.00) | — | |
| SCHEMBL11016133 | 0.93 | — | — | |
| SCHEMBL7459731 | 0.93 | — | — | |
| Bromide SCHEMBL31527773 | 0.93 | — | — | |
| Ammonia Solution, Strong SCHEMBL10590100 | 0.93 | — | — | |
| Succinimide SCHEMBL993083 | 0.93 | CRBN (0.93) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032502-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | CELGENE CORPORATION (US) | 2025-01-30 | — | — | US | claimed |
| CN-118599871-A | Gene ubiE for improving E.coli pentanediamine tolerance and application thereof | 南京工业大学 | 2024-09-06 | — | — | CN | claimed |
| US-12064437-B2 | Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | claimed |
| EP-3145513-B1 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | CELGENE CORP (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4221712-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | Celgene Corporation (US) | 2023-08-09 | — | — | EP | claimed |
| US-20230159490-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-20220160720-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | CELGENE CORPORATION (US) | 2022-05-26 | — | — | US | claimed |
| WO-2022072576-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | CELGENE CORPORATION (US) | 2022-04-07 | — | — | WO | claimed |
| CN-108245518-A | Utilize the method for two one for treating cancers of 3- (4- ((4- (morpholinomethyl) benzyl) oxygroup) -1- oxoisoindoline diindyl -2- bases) piperidines -2,6- | 细胞基因公司 | 2018-07-06 | — | — | CN | claimed |
| CN-105377831-B | Synthesis of 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2, 6-dione | 细胞基因公司 | 2018-02-02 | — | — | CN | claimed |
| CN-101959856-A | Preparation of lenalidomide | REDDYS LAB LTD | 2011-01-26 | — | — | CN | claimed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | claimed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | claimed |
| WO-2026098548-A1 | PROTEIN DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF, AND METHOD | 四川科伦博泰生物医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098644-A1 | TARGETED PROTEIN DEGRADATION AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京森妙生物科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-116457344-B | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-1671415-A | anti-CD 26 monoclonal antibodies as a treatment for diseases associated with cells expressing CD26 | UNIV TEXAS (US) | 2005-09-21 | — | — | CN | disclosed |
| EP-0288685-B1 | USE OF PYRROLIDONE DERIVATIVES AS ANTI-AMNESTIC AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-05-26 | — | — | EP | disclosed |
| US-4833156-A | Treating amnesia with a pyrrolidone derivative | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-05-23 | — | — | US | disclosed |
| EP-0288685-A2 | Use of pyrrolidone derivatives as anti-amnestic agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 1988-11-02 | — | — | EP | disclosed |